• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base

    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University

  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base

    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+

      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University

UoM-University of Toronto joint research fund open

The University of Manchester and the University of Toronto are contributing matching funds to support collaborative research initiatives through a joint call for proposals. The new joint pump-priming fund with Toronto is now open; further details are attached and applications should be submitted online using SmartSurvey <https://www.smartsurvey.co.uk/s/UoM-UofT/> . The deadline for submission is Friday 30 November 2018 (midnight Toronto time).

Any queries can be directed to Joanne.Jacobs@manchester.ac.uk in International Development.

For further information, please see UoM_UofT joint call document final version

New Graphene Business Bounces out of The University of Manchester

Dr Maria Iliut and Dr Aravind Vijayaraghavan

The business was founded by two University of Manchester academics, Dr Maria Iliut and Dr Aravind Vijayaraghavan. Both founders are world experts in graphene, and its use in making rubbers and elastomers stronger and more durable.

Grafine Ltd will be based at The University of Manchester’s Innovation Centre on Grafton Street and will use the University’s world-class facilities including the brand-new Graphene Engineering Innovation Centre (GEIC) for its product development work.

Grafine is offering a range of technical development services to manufacturing companies from around the world who wish to profit from the performance benefits that graphene can add to their products.

Elastomers and rubbers are used world over in products such as tyres, shoes, gloves, industrial components, construction materials, coatings and medical devices. The global market size for rubber and elastomer products is forecast to be more than £70 billion by 2021.

Grafine Ltd is looking to exploit the potential of this massive global market and has already excited interest from global manufacturers of elastomer and rubber products. Grafine is currently negotiating development contracts with such companies.

Dr. Vijayaraghavan, who has been at the forefront of research into graphene for more than a decade, said:

“We are very excited to launch Grafine Ltd because we have the specialist skills and know-how to help global manufacturing companies use new 2-dimensional materials like graphene effectively and cheaply.’

Graphene Stretch Sequence

He continued: “Businesses in many sectors are continually striving to improve the properties of elastomeric compounds in order to enhance product performance in both existing and new applications. Graphene can further enhance the already excellent properties of rubber and elastomers by improving their strength, elasticity, flexibility, thermal stability, resistance to chemicals and durability. With the support of Grafine Ltd, manufacturing companies will be able to give product designers even greater flexibility when they create new products.

“By working with Grafine Ltd, manufactures will be able to accelerate the speed with which they can bring these new elastomer composites to market while reducing risk and lowering cost”.

Dr. Iliut, the academic co-founder and Chief Technical Officer of Grafine, added: “

“Our business, Grafine Ltd, offers a range of consultancy services to companies wishing to exploit the benefits that these nano-materials can bring to their elastomeric products and coatings. Grafine will also sign commercial deals to license its know-how and patents allowing knowledge and technology transfer to its industrial customers.”

The University’s wholly owned subsidiary, Graphene Enabled Systems Ltd, has supported the academic founders and, with assistance from UMI3 Ltd (the University’s IP commercialisation company), created Grafine Ltd.

Its CEO, Andrew Wilkinson, who represents the University on the Grafine Ltd board, is very optimistic about Grafine’s future. “Grafine offers manufacturers the skills and know-how in graphene-enhanced elastomer and rubber composites and coatings that would take them decades to develop in-house. As the company builds its customer base and grows we predict it will have a major impact on the use of 2-dimensional materials in the global rubber and elastomer market.”

For further information, please contact Dr Maria Iliut 

Multicentre randomised controlled trial confirms the significant benefits of Phagenyx® treatment for tracheostomised stroke patients with dysphagia

University of Manchester spin-out, Phagenesis Ltd, a pioneering leader in the treatment of dysphagia, is pleased to announce today the publication of its most recent randomised controlled trial (PHAST-TRAC) in the journal Lancet Neurology read more.

Reinhard Krickl, CEO of Phagenesis, said: “The publication of the excellent PHAST-TRAC results in such a well-positioned peer-reviewed journal is a big achievement for Phagenesis. It emphasises the high clinical relevance of the benefits of Phagenyx treatment as demonstrated in the trial, addressing a genuine unmet medical need.

Around 12.5% of all stroke patients admitted to hospitals undergo mechanical ventilation and 16.3% of them receive a tracheostomy.1  Safe removal of the tracheostomy cannula is a major goal in the rehabilitation of tracheostomised patients to reduce the risk of respiratory complications, death and duration of hospitalisation.1-3 However, swallowing problems substantially delay the removal of the tube after breathing has stabilised.2,4-5

Oern Stuge, MD, Chairman of Phagenesis, stated: “These patients don’t have access to an efficient treatment that addresses the underlying neurological cause of dysphagia. With the company’s technology, we can help many patients by improving their outcomes whilst reducing the risks and costs that come with this condition.” 

The PHAST-TRAC results confirm that tracheostomised stroke patients with swallowing problems can benefit from treatment with Pharyngeal Electrical Stimulation (PES), a novel therapy based on ground-breaking research. Tracheostomy decannulation (removal of cannula) was achieved safely in 49% of patients from the PES group vs 9% in the control groupMoreover, patients who responded to PES treatment had an average reduction in hospital length of stay of 22 days.6

The North of England Life Sciences Accelerator: application now open

The North of England Life Sciences Accelerator (NELSA) is looking for early stage businesses & those with a business idea in the life science and healthcare sector.

An integrated programme of support, NELSA is a unique collaboration between the BioCity Group, BioHub at Alderley Park, Alderley Park, The N8 Research Partnership, the Northern Health Science Alliance, Alderley Park Ventures and Catapult Ventures.

Successful applicants will be invited to join NELSA and benefit from:

*        A place on the BioCity Accelerator programme

*        Seed funding via Catapult Ventures & Alderley Park Ventures

*        1:1 coaching

*        Mentorship via the UK wide Expert Network

*        Access to clinicians / clinical validation via the NHSA

*        Advice & introductions to investors to secure further funding

*        Free virtual tenancy at BioHub at Alderley Park

*        Access to shared facilities & analytical laboratory at Alderley Park

Application deadline: 17th September 2018

To apply or find out more about NELSA, please visit https://nelsa.eventbrite.co.uk

Clive Rowland appointed as Associate Vice-President for Intellectual Property

CEO of UMI3 Ltd assumes Associate Vice-President role.

Clive Rowland has been appointed as the University’s Associate Vice-President for Intellectual Property (IP) Matters. The new role will take effect in January 2019.

Clive will step down as Chief Executive Officer (CEO) of UMI3 Ltd (The University of Manchester Inspire, Invent, Innovate Ltd) following the appointment of a new CEO, the search for which has already begun.

This new post recognises the importance of IP to the University.

The Associate Vice-President role will be part-time and Clive will work closely with Professor Luke Georghiou, Deputy President and Deputy Vice-Chancellor, and other senior colleagues, to inform and advise on IP policy, IP good practice and benchmarking; IP aspects of strategic alliances and contracts; and Clive will also act as an IP ambassador for the University.

Clive co-founded, and was at the helm of, one of the UK’s earliest formed university commercialisation companies (UMIST Ventures Limited) which was established in 1988. Clive has led and evolved UMI3 since its formation in 2004 to become one of Europe’s leading university technology transfer organisations.

Over the years Clive has been active in numerous successful commercial transactions; presented at key international spin-out and licensing conferences; acted as an expert contributor on university IP to national committees and inquiries; and been a board and committee member of relevant professional networks and associations such as the British Venture Capital Association.

A Fellow of the Institute of Directors and of the Chartered Institute of Marketing, he received the Italian Order of Merit for services in promoting Manchester’s business relations with Italy.